Gen1E-1124 is under clinical development by GEn1E Lifesciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.
The company’s lead development program, istaroxime, is being developed for the treatment of acute decompensated heart failure (ADHF) and cardiogenic shock; Aerosurf, a lucinactant for inhalation, and ...
Discover top medications for 'treating Respiratory Distress Syndrome ... Peramivir is prescribed for the treatment of acute uncomplicated influenza in patients 18 years of age and above who ...
The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...
“We believe outcomes for patients experiencing or at risk of acute respiratory distress syndrome, of which pneumonia remains the most prevalent risk factor, can be improved through restoration ...